Enoxacin

Catalog No.S1756 Batch:S175603

Print

Technical Data

Formula

C15H17FN4O3
Molecular Weight 320.32 CAS No. 74011-58-8
Solubility (25°C)* In vitro DMSO 32 mg/mL (99.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 1.6mg/ml (5.00mM) Taking the 1 mL working solution as an example, add 50 μL of 32 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 0.23mg/ml (0.72mM) Taking the 1 mL working solution as an example, add 50 μL of 4.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Enoxacin (AT-2266, CI919, Pd107779, NSC 629661) is an oral broad-spectrum fluoroquinolone antibacterial agent by inhibiting bacterial DNA gyrase and topoisomerase IV, used to treat a wide variety of infections.
Targets
Topoisomerase II [1] Topoisomerase IV [1]
In vitro Enoxacin, a fluoroquinolone used as an antibacterial compound, enhances the production of miRNAs with tumor suppressor functions by binding to the miRNA biosynthesis protein TAR RNA-binding protein 2 (TRBP). [1] This compound binds to the DNA active site and alters the breakage/reunion activity of the enzyme. It stimulates cleavage of both relaxed and supercoiled forms of DNA in the absence of ATP, whereas CcdB induces cleavage only after many cycles of ATP-dependent breakage and reunion. [2] This chemical dose dependently reduces the number of osteoclasts differentiating in mouse marrow cultures stimulated with 1,25-dihydroxyvitamin D(3), as well as markers of osteoclast activity, and the number of resorption lacunae formed on bone slices. It inhibits osteoclast formation at concentrations where osteoblast formation is not altered. [3] This agent dose-dependently reduces the number of multinuclear cells expressing tartrate-resistant acid phosphatase (TRAP) activity produced by RANK-L-stimulated osteoclast precursors. It directly inhibits osteoclast formation without affecting cell viability by a novel mechanism that involves changes in posttranslational processing and trafficking of several proteins with known roles in osteoclast function. [4] This compound is able to decrease cell viability, induce apoptosis, cause cell cycle arrest, and inhibit the invasiveness of prostate cancer (PCa) cell lines. It is also effective in restoring the global expression of miRNAs in prostate cancer (PCa) cell lines. [5]

Protocol (from reference)

References

  • https://pubmed.ncbi.nlm.nih.gov/21368194/
  • https://pubmed.ncbi.nlm.nih.gov/9341164/
  • https://pubmed.ncbi.nlm.nih.gov/19630402/
  • https://pubmed.ncbi.nlm.nih.gov/22474295/
  • https://pubmed.ncbi.nlm.nih.gov/23644875/

Selleck's Enoxacin Has Been Cited by 5 Publications

Comprehensive profiling of RNA modification-related genes identifies RNA m7G binding protein CBP20 as a therapeutic target for tumor growth inhibition [ Exp Mol Med, 2025, 57(9):1978-1995] PubMed: 40887503
DNA damage triggers squamous metaplasia in human lung and mammary cells via mitotic checkpoints [ Cell Death Discov, 2023, 9(1):21] PubMed: 36681661
Genomic instability in individuals with sex determination defects and germ cell cancer [ Cell Death Discov, 2023, 9(1):173] PubMed: 37217472
The NS4A Protein of Classical Swine Fever Virus Suppresses RNA Silencing in Mammalian Cells [ J Virol, 2022, 96(15):e0187421] PubMed: 35867575
The Capsid Protein of Semliki Forest Virus Antagonizes RNA Interference in Mammalian Cells. [ J Virol, 2020, 17;94(3) pii: e01233-19] PubMed: 31694940

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.